title: Central nervous system involvement in gyrate atrophy of the choroid and retina with hyperornithinaemia.
abstract: In gyrate atrophy of the choroid and retina with hyperornithinaemia (GA), a genetically determined deficiency of ornithine delta-aminotransferase activity leads to high ornithine concentrations in body fluids. GA is characterized by centripetally progressing retinal and choroidal destruction and selective atrophy with tubular aggregates in type II skeletal muscle fibres. These findings have been suggested to be mediated by hyperornithinaemia-induced deficiency of high-energy creatine phosphate. As abnormal brain magnetic resonance images and electroencephalograms are found in another disorder of creatine metabolism, guanidinoacetate methyltransferase deficiency, we investigated the central nervous system involvement in GA, which seems to be associated with a milder degree of phosphocreatine deficiency. We compared 23 untreated GA patients with age-matched healthy controls, and with 9 patients who had received creatine or creatine precursor supplementation daily for several years. The mean age of the patients (32 +/- 18 years) was similar to that of the controls (36 +/- 22 years). The MRI or EEG findings of the patients on creatine supplementation did not differ from those of the untreated group. Brain MRI revealed degenerative lesions in the white matter in 50% of the GA patients, and 70% of the patients had premature atrophic changes, with a striking increase in the number of Virchow's spaces. Of the patients whose EEG was recorded, 58% had abnormal slow background activity, focal lesions or high-amplitude beta rhythm (> 50 microV). The EEG findings were not associated with the MRI changes or with the age or the sex of the patients. Early degenerative and atrophic brain changes and abnormal EEG are thus features of GA, in addition to the well-characterized eye and muscle manifestations.
authors.affiliation: Department of Diagnostic Radiology, University of Turku, Finland.
authors.forename: M
authors.initials: M
authors.lastname: Valtonen
authors.forename: K
authors.initials: K
authors.lastname: Näntö-Salonen
authors.forename: S
authors.initials: S
authors.lastname: Jääskeläinen
authors.forename: K
authors.initials: K
authors.lastname: Heinänen
authors.forename: A
authors.initials: A
authors.lastname: Alanen
authors.forename: O J
authors.initials: OJ
authors.lastname: Heinonen
authors.forename: N
authors.initials: N
authors.lastname: Lundbom
authors.forename: M
authors.initials: M
authors.lastname: Erkintalo
authors.forename: O
authors.initials: O
authors.lastname: Simell
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001921:Brain / Q000473:pathology; D002490:Central Nervous System / Q000473:pathology*; D002648:Child; D002675:Child, Preschool; D002829:Choroid / Q000473:pathology*; D003401:Creatine / Q000494:pharmacology; D004569:Electroencephalography; D005260:Female; D015799:Gyrate Atrophy / Q000473:pathology*; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009952:Ornithine / Q000097:blood / Q000378:metabolism*; D009953:Ornithine-Oxo-Acid Transaminase / Q000097:blood / Q000172:deficiency*; D012160:Retina / Q000473:pathology*
chemical_list: D009952:Ornithine; D009953:Ornithine-Oxo-Acid Transaminase; D003401:Creatine